1.55
price up icon6.16%   +0.09
after-market  After Hours:  1.56  0.01   +0.65%
loading
Pacific Biosciences of California Inc stock is currently priced at $1.55, with a 24-hour trading volume of 16.77M. It has seen a +6.16% increased in the last 24 hours and a -57.42% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.42 pivot point. If it approaches the $1.63 resistance level, significant changes may occur.

Pacific Biosciences of California Inc Stock (PACB) Financials Data

Pacific Biosciences of California Inc (PACB) Revenue 2024

PACB reported a revenue (TTM) of $200.52 million for the quarter ending December 31, 2023, a +56.29% rise year-over-year.
loading

Pacific Biosciences of California Inc (PACB) Net Income 2024

PACB net income (TTM) was -$306.74 million for the quarter ending December 31, 2023, a +2.39% increase year-over-year.
loading

Pacific Biosciences of California Inc (PACB) Cash Flow 2024

PACB recorded a free cash flow (TTM) of -$268.02 million for the quarter ending December 31, 2023, a +4.33% increase year-over-year.
loading

Pacific Biosciences of California Inc (PACB) Earnings per Share 2024

PACB earnings per share (TTM) was -$1.21 for the quarter ending December 31, 2023, a +13.57% growth year-over-year.
loading

Pacific Biosciences of California Inc Stock (PACB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Meline David W
Director
Mar 06 '24
Buy
4.40
40,000
176,160
40,000
HENRY CHRISTIAN O
See Remarks
Mar 04 '24
Sale
4.87
14,177
69,056
2,596,670
Van Oene Mark
See Remarks
Mar 04 '24
Sale
4.87
9,186
44,745
1,668,826
Kim Susan G.
See Remarks
Mar 04 '24
Sale
4.87
5,275
25,695
712,260
Farmer Michele
See Remarks
Mar 04 '24
Sale
4.87
2,968
14,457
217,216
MOHR MARSHALL
Director
Mar 01 '24
Option Exercise
4.45
25,000
111,250
110,000
HENRY CHRISTIAN O
See Remarks
Feb 20 '24
Sale
5.26
1,979
10,412
1,005,078
Kim Susan G.
See Remarks
Feb 20 '24
Sale
5.26
831
4,372
282,758
HENRY CHRISTIAN O
See Remarks
Feb 16 '24
Sale
5.96
79,038
470,908
1,007,057
Van Oene Mark
See Remarks
Feb 16 '24
Sale
5.96
33,560
199,950
876,611
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
medical_devices PHG
$19.98
price up icon 0.00%
medical_devices STE
$199.51
price down icon 0.65%
$298.98
price down icon 0.78%
medical_devices ZBH
$119.43
price up icon 0.08%
$130.71
price down icon 2.67%
medical_devices EW
$85.94
price down icon 0.59%
Cap:     |  Volume (24h):